Hims & Hers Health, Inc. (NYSE:HIMS) Holdings Lowered by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP cut its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 44.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,289,704 shares of the company's stock after selling 1,032,158 shares during the period. Hims & Hers Health accounts for about 3.6% of Divisadero Street Capital Management LP's investment portfolio, making the stock its 8th biggest holding. Divisadero Street Capital Management LP owned 0.59% of Hims & Hers Health worth $31,185,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership increased its holdings in shares of Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the period. Vanguard Group Inc. grew its holdings in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd acquired a new position in Hims & Hers Health in the 4th quarter valued at approximately $41,104,000. Renaissance Technologies LLC raised its position in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in Hims & Hers Health by 613.9% during the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock worth $30,878,000 after buying an additional 1,098,148 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HIMS has been the subject of a number of analyst reports. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. UBS Group restated a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Piper Sandler restated a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Stock Up 1.2 %

HIMS stock traded up $0.64 during midday trading on Friday, reaching $52.04. 61,754,901 shares of the company's stock traded hands, compared to its average volume of 18,348,268. The firm's fifty day moving average price is $32.97 and its 200-day moving average price is $32.43. Hims & Hers Health, Inc. has a 52 week low of $12.07 and a 52 week high of $72.98. The company has a market cap of $11.65 billion, a price-to-earnings ratio of 118.28 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's revenue was up 110.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.05 EPS. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $43.01, for a total value of $498,098.81. Following the completion of the transaction, the chief financial officer now owns 107,789 shares in the company, valued at $4,636,004.89. This represents a 9.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the sale, the chief executive officer now owns 97,687 shares in the company, valued at $5,692,221.49. The trade was a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 650,500 shares of company stock worth $25,790,311. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.